vs

Side-by-side financial comparison of NACCO INDUSTRIES INC (NC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

NACCO INDUSTRIES INC is the larger business by last-quarter revenue ($66.8M vs $35.5M, roughly 1.9× RECURSION PHARMACEUTICALS, INC.). NACCO INDUSTRIES INC runs the higher net margin — -5.8% vs -304.2%, a 298.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -5.2%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 11.9%).

NACCO Industries, Inc. is an American publicly traded holding company, headquartered in Cleveland, Ohio. Through a portfolio of mining and natural resources businesses, the company operates under three business segments: Coal Mining, North American Mining, and Minerals Management. The Coal Mining segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The North American Mining se...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

NC vs RXRX — Head-to-Head

Bigger by revenue
NC
NC
1.9× larger
NC
$66.8M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+686.9% gap
RXRX
681.7%
-5.2%
NC
Higher net margin
NC
NC
298.5% more per $
NC
-5.8%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
11.9%
NC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NC
NC
RXRX
RXRX
Revenue
$66.8M
$35.5M
Net Profit
$-3.8M
$-108.1M
Gross Margin
18.0%
59.8%
Operating Margin
11.3%
-304.8%
Net Margin
-5.8%
-304.2%
Revenue YoY
-5.2%
681.7%
Net Profit YoY
-150.8%
39.6%
EPS (diluted)
$-0.53
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NC
NC
RXRX
RXRX
Q4 25
$66.8M
$35.5M
Q3 25
$76.6M
$5.2M
Q2 25
$68.2M
$19.2M
Q1 25
$65.6M
$14.7M
Q4 24
$70.4M
$4.5M
Q3 24
$61.7M
$26.1M
Q2 24
$52.3M
$14.4M
Q1 24
$53.3M
$13.8M
Net Profit
NC
NC
RXRX
RXRX
Q4 25
$-3.8M
$-108.1M
Q3 25
$13.3M
$-162.3M
Q2 25
$3.3M
$-171.9M
Q1 25
$4.9M
$-202.5M
Q4 24
$7.6M
$-178.9M
Q3 24
$15.6M
$-95.8M
Q2 24
$6.0M
$-97.5M
Q1 24
$4.6M
$-91.4M
Gross Margin
NC
NC
RXRX
RXRX
Q4 25
18.0%
59.8%
Q3 25
13.0%
-183.8%
Q2 25
10.0%
-4.9%
Q1 25
14.7%
-48.0%
Q4 24
12.0%
-181.4%
Q3 24
11.7%
53.7%
Q2 24
13.4%
36.2%
Q1 24
13.2%
19.1%
Operating Margin
NC
NC
RXRX
RXRX
Q4 25
11.3%
-304.8%
Q3 25
8.8%
-3327.6%
Q2 25
-0.1%
-916.8%
Q1 25
11.7%
-1297.9%
Q4 24
5.5%
-4042.4%
Q3 24
31.9%
-377.1%
Q2 24
14.1%
-697.4%
Q1 24
8.9%
-698.4%
Net Margin
NC
NC
RXRX
RXRX
Q4 25
-5.8%
-304.2%
Q3 25
17.3%
-3135.3%
Q2 25
4.8%
-894.2%
Q1 25
7.5%
-1373.3%
Q4 24
10.7%
-3935.5%
Q3 24
25.4%
-367.5%
Q2 24
11.4%
-676.6%
Q1 24
8.6%
-662.4%
EPS (diluted)
NC
NC
RXRX
RXRX
Q4 25
$-0.53
$-0.17
Q3 25
$1.78
$-0.36
Q2 25
$0.44
$-0.41
Q1 25
$0.66
$-0.50
Q4 24
$0.99
$-0.56
Q3 24
$2.14
$-0.34
Q2 24
$0.81
$-0.40
Q1 24
$0.61
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NC
NC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$49.7M
$743.3M
Total DebtLower is stronger
$100.8M
$9.6M
Stockholders' EquityBook value
$429.2M
$1.1B
Total Assets
$661.2M
$1.5B
Debt / EquityLower = less leverage
0.23×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NC
NC
RXRX
RXRX
Q4 25
$49.7M
$743.3M
Q3 25
$52.7M
$659.8M
Q2 25
$49.4M
$525.1M
Q1 25
$61.9M
$500.5M
Q4 24
$72.8M
$594.4M
Q3 24
$63.1M
$427.6M
Q2 24
$62.4M
$474.3M
Q1 24
$61.8M
$296.3M
Total Debt
NC
NC
RXRX
RXRX
Q4 25
$100.8M
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$99.4M
$19.0M
Q3 24
$20.5M
Q2 24
$29.0M
$22.9M
Q1 24
$28.4M
Stockholders' Equity
NC
NC
RXRX
RXRX
Q4 25
$429.2M
$1.1B
Q3 25
$426.4M
$1.0B
Q2 25
$413.1M
$919.1M
Q1 25
$409.1M
$933.9M
Q4 24
$404.9M
$1.0B
Q3 24
$397.3M
$524.6M
Q2 24
$384.1M
$584.4M
Q1 24
$381.6M
$401.2M
Total Assets
NC
NC
RXRX
RXRX
Q4 25
$661.2M
$1.5B
Q3 25
$637.6M
$1.4B
Q2 25
$631.3M
$1.3B
Q1 25
$634.2M
$1.3B
Q4 24
$631.7M
$1.4B
Q3 24
$597.4M
$726.5M
Q2 24
$560.1M
$775.9M
Q1 24
$538.0M
$557.8M
Debt / Equity
NC
NC
RXRX
RXRX
Q4 25
0.23×
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.25×
0.02×
Q3 24
0.04×
Q2 24
0.08×
0.04×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NC
NC
RXRX
RXRX
Operating Cash FlowLast quarter
$11.4M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NC
NC
RXRX
RXRX
Q4 25
$11.4M
$-46.1M
Q3 25
$42.3M
$-117.4M
Q2 25
$-7.8M
$-76.4M
Q1 25
$5.0M
$-132.0M
Q4 24
$25.2M
$-115.4M
Q3 24
$2.8M
$-59.2M
Q2 24
$4.1M
$-82.2M
Q1 24
$-9.8M
$-102.3M
Free Cash Flow
NC
NC
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
NC
NC
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
NC
NC
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
NC
NC
RXRX
RXRX
Q4 25
Q3 25
3.19×
Q2 25
-2.39×
Q1 25
1.03×
Q4 24
3.33×
Q3 24
0.18×
Q2 24
0.68×
Q1 24
-2.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NC
NC

Transferred Over Time$42.7M64%
Transferred At Point In Time$24.1M36%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons